09:20 AM EDT, 07/09/2025 (MT Newswires) -- Eledon Pharmaceuticals ( ELDN ) has agreed to collaborate with Sernova Biotherapeutics to evaluate tegoprubart in patients with type 1 diabetes, Sernova said Wednesday.

Under the agreement, Eledon will supply tegoprubart to replace tacrolimus in Cohort C of Sernova's phase 1/2 cell pouch bio-hybrid organ trial in patients with type 1 diabetes, according to a statement.

Shares of Eledon were up 7% in recent premarket activity Wednesday.